A concerning new warning from the World Health Organization is raising alarms about growing resistance to a widely used HIV drug. GSK's Tivicay (dolutegravir), a key component of many modern antiretroviral regimens, is becoming less effective in certain regions due to increasing drug resistance.
This video unpacks the WHO's evidence and guidance on the issue. We'll explain what drug resistance is, how it develops, and why it poses such a threat in the fight against HIV/AIDS. You'll learn about the specific Tivicay resistance mutations being reported across multiple countries.
Featuring insights from HIV experts and researchers, we'll analyze the factors driving accelerated resistance, from lack of adherence and viral monitoring to use of older ineffective regimens. The stakes are high, as drug resistance can lead to treatment failure and viral rebound.
While the future drug pipeline looks promising, we can't rely solely on new medications. This video will examine WHO's recommendations and best practices to minimize emergence of resistance, such as enhanced testing, stronger adherence support, and smarter regimen prescribing.
As we make progress getting HIV treatment to more people globally, we must confront this growing obstruction head-on. Join us for an in-depth look at the battle against Tivicay resistance - a threat that could derail hard-won achievements if left unchecked.
#HIV #TivicayResistance #DrugResistance #Dolutegravir #Antiretrovirals #HIVTreatment #WHO #AIDSPandemic #PublicHealth #MedicationAdherence #ViralLoad #NewHIVDrugs
Негізгі бет The Rising Resistance: GSK's HIV Med Tivicay
Пікірлер